Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer

Open access
Yaeger, Rona, Cercek, Andrea, Chou, Joanne F., Sylvester, Brooke E., Kemeny, Nancy E., Hechtman, Jaclyn F., Ladanyi, Marc, Rosen, Neal, Weiser, Martin R., Capanu, Marinela, Solit, David B., D'Angelica, Michael I., Vakiani, Efsevia, Saltz, Leonard B. · 2014 · Cancer

Abstract

BACKGROUND: BRAF mutations occur in 5% to 11% of patients with metastatic colorectal cancer (mCRC) and have been associated with poor prognosis. The current study was undertaken to determine the clinicopathologic characteristics, PIK3CA (phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit alpha) mutation frequency, and outcomes after metastasectomy in patients with BRAF‐mutant mCRC. METHODS: Data from 1941 consecutive patients with mCRC who underwent KRAS/BRAF mutation testing between 2009 and 2012 at a single institution were identified to identify BRAF‐mutant mCRC cases (92 cases). BRAF wild‐type mCRC cases from 2011 (423 cases) served as a control group. RESULTS: BRAF‐mutated mCRC was found to be significantly associated with older age at diagnosis, female sex, right‐sided location, poorly differentiated morphology, and mucinous histology compared with wild‐type cases. BRAF‐mutant cases more frequently progressed from stage III disease (32% vs 17%; P = .003) and among those patients with stage III disease, T4 disease was more common (48% vs 27%; P = .05). PIK3CA was found to be co‐mutated in 5% of BRAF‐mutant tumors versus 17% of KRAS‐mutant tumors (P < .01) and 4% of BRAF/KRAS wild‐type cases. Patients with BRAF‐mutated mCRC presented more frequently with peritoneal involvement (26% vs 14%; P < 0.01) and less frequently with liver‐limited metastases (41% vs 63%; P < .01). Patients with BRAF‐mutated mCRC were less likely to undergo metastasectomy (41% vs 26% at 2 years from diagnosis of metastatic disease; P < .01) and were found to have lower overall survival (P < .01) after metastasectomy. CONCLUSIONS: BRAF‐mutant mCRC is associated with worse clinical outcome. Patients with BRAF‐mutant tumors more commonly develop peritoneal metastases, less frequently present with disease limited to the liver, and have shorter survival after metastasectomy compared with patients with BRAF wild‐type tumors. Cancer 2014;120:2316–2324. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.28729

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 203

Metadata

Authors
Yaeger, R., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N., Weiser, M. R., Capanu, M., Solit, D. B., D'Angelica, M. I., Vakiani, E., & Saltz, L. B.
Venue
Cancer
Publisher
Wiley
Published
2014-04-15
Volume
120
Issue
15
Pages
2316-2324
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1597604324
Cited by
203
References
4
FWCI
8.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.1002/cncr.28729
The paper
Yaeger, R., Cercek, A., Chou, J. F., Sylvester, B. E., Kemeny, N. E., Hechtman, J. F., Ladanyi, M., Rosen, N., Weiser, M. R., Capanu, M., Solit, D. B., D'Angelica, M. I., Vakiani, E., & Saltz, L. B. (2014). BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. https://doi.org/10.1002/cncr.28729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.